[Clinical-electrophysiologic studies on the actions of the anti-arrhythmic substance AWD-G256 in man].
The effects of the new antiarrhythmic drug AWD-G256 (1) were investigated by clinical electrophysiology (His bundle electrography, programmed electrical stimulation) in 19 patients with supraventricular tachycardias but without structural heart disease. In a maximal dosage of 0.45 mg/kg body mass 1 only minimally affects electrophysiological parameters of the impulse formation and conduction. At this time the therapeutic value of 1 is not clear.
Volkmann
H
H
Abteilung für Kardiologie und Angiologie, Friedrich-Schiller-Universität Jena.
Hoffmann
A
A
Kühnert
H
H
Dannberg
G
G
Heinke
M
M
Reimann
I
I
Marschner
J P
JP
Farker
K
K
D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001577:Benzophenones / Q000494:pharmacology* / Q000627:therapeutic use; D002036:Bundle of His / Q000187:drug effects / Q000502:physiology; D004558:Electric Stimulation; D004594:Electrophysiology; D006329:Heart Conduction System / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006835:Hydrazones / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011689:Purkinje Cells / Q000187:drug effects; D012849:Sinoatrial Node / Q000187:drug effects; D013617:Tachycardia, Supraventricular / Q000188:drug therapy / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D001577:Benzophenones; D006835:Hydrazones; C080444:(Z)-2-amino-5-chlorobenzophenonamidinohydrazone acetate
Klinisch-elektrophysiologische Untersuchungzen zur Wirkung der antiarrhythmischen Substanz AWD-G256 beim Menschen.